Pursuant to The Pharmaceutical Act and Regulations and the Policy Statement on Practice Directions, CPhM welcomes the feedback of all stakeholders, including members of the public, through a transparent consultation process.

At present, there are no active consultations.

2024 Closed Consultations

Information about closed consultations can be found here:

Consultation on Proposed Bylaw Draft


In 2020, Council of the College of Pharmacists of Manitoba (CPhM) initiated a comprehensive review of its current governance framework. This process aimed to modernize the framework and enhance its alignment with the principles of transparency, accountability, and a commitment to the public interest. Upon completing this initial review, the Governance Committee, in close collaboration with CPhM Council, proceeded to refine the bylaws, incorporating the recommended changes.  

Town Hall Follow-Up: Q&A Insights 

On January 29, 2024, a virtual town hall meeting was held as a supplement to the consultation process for proposed amendments to the CPhM Bylaws. All registrants were informed of the town hall and had the opportunity to attend the virtual event. During the meeting, attendees were presented with the highlights of the draft bylaws based on feedback received and engaged in a live Q&A session. Many questions had overlapping themes and subjects.

The following document summarizes the questions asked during the event, grouped by common themes: CPhM Townhall Q&A

If you have any comments or questions, please send to 

Changes to the Electronic Transmission of Prescriptions Practice Direction and the Manitoba Prescribing Practices Program (M3P)

Thank you to everyone who participated in this consultation on proposed changes to the Electronic Transmission of Prescriptions Practice Direction and the Manitoba Prescribing Practices Program (M3P).

CPhM invited feedback from all registrants, stakeholders, and the public on the following proposed changes:

  • Allowing transfers of CDSA prescriptions
  • Updated Joint Practice Direction for Electronic Transmission of Prescriptions
  • Elimination of the Joint Statement on Prescribing Practices: Doctor/Pharmacist Relationships
  • Replacement of the personalized M3P paper pads with standardized templates
  • Addition of Codeine Products to the list of drugs covered under the M3P

All feedback and comments received are reviewed and considered by Council.

If you have any questions, please email